Increlex

Mecasermin, the active ingredient in Increlex, is an insulin‑like growth factor‑1 (IGF‑1) analog presented as a solution for injection for subcutaneous use. It is indicated for children with growth failure due to primary IGF‑1 deficiency or due to a growth‑hormone gene deletion.

GNH USA supplies Increlex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across EU and global markets.

Increlex (mecasermin) is used to address growth disorders that stem from deficiencies in the IGF‑1 pathway.

- Primary IGF‑1 deficiency: promotes linear growth and improves height velocity in affected children. - Growth‑hormone gene deletion: stimulates growth in children lacking functional growth‑hormone production. - Severe IGF‑1‑related growth failure: provides an IGF‑1 replacement to achieve catch‑up growth when conventional GH therapy is ineffective.

The safety profile of Increlex includes a range of observed adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypoglycemia: low blood sugar episodes, especially when administered without adequate carbohydrate intake. - Injection site reactions: redness, swelling, or pain at the subcutaneous injection site. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort following dosing. - Lipohypertrophy: localized thickening of subcutaneous tissue.

Serious or Rare Side Effects: - Intracranial hypertension: signs of increased intracranial pressure such as headache, visual changes. - Pancreatitis: abdominal pain with elevated pancreatic enzymes. - Severe allergic reactions: rash, urticaria, or anaphylaxis. - Tumor progression: potential acceleration of pre‑existing malignancies.

Before initiating Increlex therapy, healthcare professionals should consider several precautionary measures to ensure safe use. - Blood glucose monitoring: regularly check glucose levels to detect hypoglycemia. - IGF‑1 level assessment: measure serum IGF‑1 to guide dosing and avoid excess. - Intracranial pressure evaluation: monitor for signs of increased intracranial pressure, especially in patients with prior CNS disorders. - Contraindication in active malignancy: avoid use in patients with known active cancer due to potential tumor growth stimulation. - Concomitant insulin or hypoglycemic agents: adjust doses to reduce hypoglycemia risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Increlex may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin or oral hypoglycemics: combined use can cause severe hypoglycemia. - Concurrent growth hormone therapy: may lead to excessive IGF‑1 levels and related toxicity. - High‑dose glucocorticoids: can diminish the anabolic response to mec­asermin.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: IGF‑1 can affect thyroid hormone metabolism; monitor thyroid function tests. - Diuretics: may alter fluid balance and affect IGF‑1 distribution. - Antiepileptic drugs (e.g., carbamazepine): potential induction of IGF‑1 clearance; observe clinical response.